Latest Posts › Life Sciences

Share:

Securities Litigation Against Life Sciences Companies 2024 Year in Review

Welcome to our ninth annual report on US securities class actions filed against publicly traded life sciences companies, which include pharmaceutical, biotechnology, medical device, and healthcare companies....more

2022 Year in Review: Securities Litigation Against Life Sciences Companies

We are proud to present our seventh annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against publicly traded pharmaceutical, biotechnology,...more

2021 Year in Review: Securities Litigation Against Life Sciences Companies

Summary of 2021 Trends, Themes, and Takeaways - We are proud to present our sixth annual Securities Litigation Year in Review publication, in which we analyze data for securities class actions filed nationally against...more

The Impact of COVID-19 on Disclosure Obligations for Public Companies in the Life Sciences Industry

The ongoing global outbreak of the novel coronavirus (COVID-19) raises important considerations for life sciences companies subject to U.S. Securities and Exchange Commission (“SEC”) disclosure and reporting requirements. As...more

4 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide